Apple
AAPL
Taylor Morrison Home
TMHC
D.R. Horton
DHI
4
Petroleo Brasileiro SA Petrobras
PBR
5
Vale SA
VALE
US Stock MarketDetailed Quotes
RXRX Recursion Pharmaceuticals
- 5.970
- -0.200-3.24%
Close Mar 27 16:00 ET
- 6.027
- +0.057+0.95%
Post 19:59 ET
2.40BMarket Cap-3.53P/E (TTM)
6.300High5.950Low14.74MVolume6.040Open6.170Pre Close89.99MTurnover3.85%Turnover RatioLossP/E (Static)401.99MShares12.36052wk High2.32P/B2.28BFloat Cap5.60052wk Low--Dividend TTM382.61MShs Float42.810Historical High--Div YieldTTM5.67%Amplitude4.540Historical Low6.104Avg Price1Lot Size
About Recursion Pharmaceuticals Company
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
Company Profile
SymbolRXRX
Company NameRecursion Pharmaceuticals
Listing DateApr 16, 2021
Issue Price18.00
Founded2013
CEODr. Christopher Gibson, PhD
MarketNASDAQ
Employees800
Fiscal Year Ends12-31
Address41 South Rio Grande Street
CitySalt Lake City
ProvinceUtah
CountryUnited States of America
Zip Code84101
Phone1-385-269-0203
Websitehttp://www.recursion.com
Company Executives
- Name
- Position
- Salary
- Dr. Christopher Gibson, PhD
- Chief Executive Officer, Director and President
- 8.61M
- Dr. David J. Mauro, M.D.
- Chief Medical Officer
- 4.31M
- Kristen Rushton
- Chief Operating Officer
- --
- Matthew Kinn
- Chief Business Officer
- --
- David Hallett, PhD
- Chief Scientific Officer
- --
- Ben R. Taylor
- Chief Financial Officer, Principal Accounting Officer and President, Recursion UK
- --
- Dr. Najat Khan, PhD
- Director, Chief Research and Development Officer and Chief Commercial Officer
- --
- Lina Nilsson
- Senior Vice President and Head, Platform
- --
- Dr. Robert M. Hershberg, M.D.,PhD
- Chairman of the Board
- 302.74K
- Dr. Franziska Michor, PhD
- Director
- --
- Elaine D. Sun
- Director
- --
- Dr. Namandje N. Bumpus, PhD
- Director
- --
- Zavain Dar, PhD
- Independent Director
- 307.74K
- Zachary Bogue, J.D.
- Independent Director
- 21.25K
- Dean Y. Li, M.D.,PhD
- Independent Director
- 300.25K
- Dr. Blake Borgeson, PhD
- Independent Director
- 292.74K
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings